Open Save New
FeedNavigator / National Library of Health Sciences
 
  
Tutkijat / Oulu
AddAla-Kokko, L.
AddAla-Kokko, T(ero)
AddAla-Korpela, M(ika)
AddAlahuhta, S.
AddAlén, M(arkku)
AddAntikainen, R.
AddAnttonen, V(uokko)
AddBiancari, F(austo)
AddBloigu, R(isto)
AddEskelinen, S.
AddFlinkkilä, T(apio)
AddHakkola, J.
AddHallman, M.
AddHartikainen, A(nna)-L(iisa)
AddHausen, H.
AddHautala, N(ina)
AddHautala, T(imo)
AddHeape, A.
AddHerzig, K(arl)-H(einz)
AddHillbom, M.
AddHiltunen, J.K.
AddHörkko, S.
AddHuikuri, H(eikki)
AddHukkanen J(anne)
AddIgnatius, J.
AddIsohanni, M.
AddJaakkola, J.
AddJaakkola, M(aritta) S.
AddJaakola, V-P.
AddJämsä, T(imo)
AddJanhonen, S.
AddJartti, T(uomas)
AddJärvelin, M(arjo)-R(iitta)
AddJokelainen, J(ari)
AddJuffer, A(ndré) H.
AddJunttila, J(uhani)
AddJuvonen, T.
AddKaarteenaho, R(iitta)
AddKajantie, E(ero)*(THL/OY)
AddKarppinen (Koivunen), P(eppi)
AddKarppinen, J(aro)
AddKarttunen, T.J.
AddKeinänen-Kiukaanniemi, S(irkka)
AddKerkelä, R(isto)
AddKesäniemi, Y(rjö) A(ntero)
AddKettunen, J(ohannes)
AddKietzmann, T(homas).
AddKivirikko, K.I.
AddKnuuttila, M.
AddKoivukangas, J.
AddKursula, P(etri)
AddKyngäs, H.
AddLarivaara, P.
AddLarmas, M.
AddLehenkari, P(etri)
AddLehtiö, L(ari)
AddLeppilahti, J.
AddLuukinen, H.
AddMainio A
AddMajamaa, K.
AddMäki, P(irjo)
AddMäkikallio, T(imo) H.
AddMännikkö, M(inna)
AddManninen, A(ki).
AddMartikainen, H(annu)
AddMiettunen, J(ouko)
AddMyllyharju, J(ohanna)
AddMyllylä, R.
AddMyllylä, V.
AddNäyhä, S(imo)
AddNeubauer, P.
AddNieminen, M(iika) T.
AddNieminen, P(entti)
AddNiinimäki, J(aakko)
AddOhukainen, P(auli)
AddOikarinen, A.
AddOikarinen, K.
AddPelkonen, O(lavi)
AddPetäjä-Repo, U.E.
AddPihlajaniemi, T(aina)
AddPirttiniemi, P(ertti)
AddPuistola, U(lla)
AddRajaniemi, H.J.
AddRäsänen, P.
AddRaustia, A.
AddRemes, A(nne)
AddRisteli, J.
AddRistiniemi, J.
AddRuddock, L.W.
AddRuokonen, A.
AddRyynänen, M.
AddSaarakkala, S.
AddSaari, A.
AddSalo, T(uula)
AddSándor, G(eorge) K.
AddSavolainen, E-R.
AddSavolainen, M.J.
AddSavolainen, O.
AddSillanpää, M(ikko).
AddSoininen, R.
AddSorri, M.
AddTaanila, A.
AddTapiainen, T(erhi)
AddTervonen, O(smo)
AddTimonen, M(arkku)
AddTurpeenniemi-Hujanen, T.
AddTuukkanen, J(uha)
AddTuulonen, A.
AddUhari, M.
AddUkkola, O(lavi)
AddUusimaa, J.
AddVainio, O.
AddVainio, S.
AddVäyrynen, J(uha) P.
AddVeijola, J(uha)
AddVeijola, R(iitta)
AddVirokannas, H.
AddVoipio, H(anna)-M(arja)
AddVuolteenaho, O.
AddWeckström, M.
AddWei, GH.
AddWierenga, R.K.
AddWinqvist, R(obert)
AddYlänne, J.
AddYlitalo, K(ari)

Scholar Chart >>



»My Articles

»Latest Feeds

»Popular Feeds
Search Feed Catalog by Name:
Critique of the "Comment" etitled "Pyrethroid exposure: not so harmless after all" by Demeneix et al. (2020) published in The Lancet Diabetes Endocrinology.Pelkonen, O(lavi)284 dayssaveRefWorks
Statement on the translocation potential by Pseudomonas chlororaphis MA342 in plants after seed treatment of cereals and peas and assessment of the risk to humans.Pelkonen, O(lavi)350 dayssaveRefWorks
Inhibition and induction of CYP enzymes in humans: an update.Pelkonen, O(lavi)355 dayssaveRefWorks
CYP-associated drug-drug interactions: A mission accomplished?Pelkonen, O(lavi)377 dayssaveRefWorks
Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on the genotoxic potential of triazine amine (metabolite common to several sulfonylurea active substances).Pelkonen, O(lavi)411 dayssaveRefWorks
Scientific statement on the coverage of bats by the current pesticide risk assessment for birds and mammals.Pelkonen, O(lavi)470 dayssaveRefWorks
Scientific Opinion on the setting of health-based reference values for metabolites of the active substance terbuthylazine.Pelkonen, O(lavi)470 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)487 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)497 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)525 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)530 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)533 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)533 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)533 dayssaveRefWorks
Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.Pelkonen, O(lavi)868 dayssaveRefWorks
Integration of epidemiological findings with mechanistic evidence in regulatory pesticide risk assessment: EFSA experiences.Pelkonen, O(lavi)897 dayssaveRefWorks
Editorial.Pelkonen, O(lavi)1007 dayssaveRefWorks
Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance.Pelkonen, O(lavi)1163 dayssaveRefWorks
Obfuscating Transparency?Pelkonen, O(lavi)1188 dayssaveRefWorks
Toxicology meets Pharmacodynamics and Pharmacokinetics - New Concepts, Models and In Vitro Approaches and Tools.Pelkonen, O(lavi)1210 dayssaveRefWorks
CYP Induction and Xeno-Sensing Receptors PXR, CAR, AHR and PPARα at the Crossroads of Toxicokinetics and Toxicodynamics.Pelkonen, O(lavi)1317 dayssaveRefWorks
Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.Pelkonen, O(lavi)1607 dayssaveRefWorks
Cardiac safety of ophthalmic timolol.Pelkonen, O(lavi)1824 dayssaveRefWorks
Upholding science in health, safety and environmental risk assessments and regulations.Pelkonen, O(lavi)1857 dayssaveRefWorks
Cardiac safety of ophthalmic timolol.Pelkonen, O(lavi)1887 dayssaveRefWorks
Response to“The Path Forward on Endocrine Disruptors Requires Focus”.Pelkonen, O(lavi)1974 dayssaveRefWorks
Tandem mass spectrometric analysis of S- and N-linked glutathione conjugates of pulegone and menthofuran and identification of P450 enzymes mediating their formation.Pelkonen, O(lavi)2047 dayssaveRefWorks
Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species.Pelkonen, O(lavi)2162 dayssaveRefWorks
Differentiation-Promoting Medium Additives for Hepatocyte Cultivation and Cryopreservation.Pelkonen, O(lavi)2258 dayssaveRefWorks
Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes.Pelkonen, O(lavi)2261 dayssaveRefWorks
Drug Metabolism - From In Vitro to In Vivo, from Simple to Complex Reflections of the BCPT Nordic Prize 2014 Awardee.Pelkonen, O(lavi)2318 dayssaveRefWorks
Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System.Pelkonen, O(lavi)2332 dayssaveRefWorks
Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer.Pelkonen, O(lavi)2420 dayssaveRefWorks
Biotransformation in vitro: An essential consideration in the quantitative invitro-to-in vivo extrapolation (QIVIVE) of toxicity data.Pelkonen, O(lavi)2513 dayssaveRefWorks
Reactive Metabolites in Early Drug Development: Predictive in Vitro Tools.Pelkonen, O(lavi)2562 dayssaveRefWorks
Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?Pelkonen, O(lavi)2699 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2838 dayssaveRefWorks
Human variation and CYP enzyme contribution in benfuracarb metabolism in human in vitro hepatic models.Pelkonen, O(lavi)2961 dayssaveRefWorks
Analytical challenges for conducting rapid metabolism characterization for QIVIVE.Pelkonen, O(lavi)2969 dayssaveRefWorks
Open letter to the European commission: scientifically unfounded precaution drives European commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles.Pelkonen, O(lavi)2975 dayssaveRefWorks
Comparative metabolism of benfuracarb in in vitro mammalian hepatic microsomes model and its implications for chemical risk assessment.Pelkonen, O(lavi)2982 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2996 dayssaveRefWorks
Estimation of health risk by using toxicokinetic modelling: A case study of polychlorinated biphenyl PCB153.Pelkonen, O(lavi)2997 dayssaveRefWorks
Effects of ospemifene on drug metabolism mediated by cytochrome p450 enzymes in humans in vitro and in vivo.Pelkonen, O(lavi)3008 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)3014 dayssaveRefWorks
Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.Pelkonen, O(lavi)3017 dayssaveRefWorks
"Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.''Pelkonen, O(lavi)3017 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)3024 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)3025 dayssaveRefWorks
Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations.Pelkonen, O(lavi)3059 dayssaveRefWorks
 XML / RSS feed
report
next »